SynthesisPharmacoEconomics2023
Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review.
Synthesis in PharmacoEconomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- DELTA: Strengthening human biological resilience with an N=1 digital health and dynamic biomarker protocol.PloS one · 2026Trial
- A service evaluation of the uptake and effectiveness of a digital delivery of the NHS health check service.BMJ open · 2024Trial
- Cost-effectiveness analysis of transcatheter aortic valve implantation for asymptomatic severe aortic stenosis across nine European countries.European heart journal open · 2026Article
- A multi-view autoencoder architecture with self-adaptive feature recalibration and confidence-aware ensemble for heart disease classification.Scientific reports · 2026Article
- Occupational and socioeconomic predictors of myocardial infarction and coronary heart disease: a machine learning analysis.BMC public health · 2026Article
- Automated Aortic Quantification Based on Artificial Intelligence: Validation Using Contrast-Enhanced and Non-Contrast CT Scans from the Same Session.Bioengineering (Basel, Switzerland) · 2026Article
- Willingness to Share Internet Use Data for Research on Early Disease Detection: Cross-Sectional Survey.Journal of medical Internet research · 2026Article
- Artificial Intelligence-enhanced Electrocardiography for Heart Failure Screening and Risk Stratification.Current heart failure reports · 2026Review
- PeakExperimental physiology · 2026Article
- Reassessing onco-exceptionalism: equity and resource allocation in immunotherapeutic cancer treatments.Journal of medical ethics · 2026Article
- Article
- Exploring the Potential of AI and Augmented Reality in Cardiovascular Disease Management: A Narrative Review.Current cardiology reviews · 2026Review
- Article
- Highlights from the Manifesto on the Health Economics of Cardiovascular Disease Prevention.PharmacoEconomics · 2025Review
- Triglyceride to high-density lipoprotein ratio as a predictor for 10-year cardiovascular disease in individuals with diabetes in Thailand.Journal of health, population, and nutrition · 2025Article
- Mining the risk: early cardiovascular detection in workers.Frontiers in medicine · 2025Article
- Telehealth for Integrated Cardiovascular and Diabetes Management: A Scoping Review.Journal of diabetes research · 2025Article
- Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.Lancet (London, England) · 2024Article
- Vascular medicine in the 21World journal of clinical cases · 2024Review
- Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.EClinicalMedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiovascular disease (CVD) is the most prominent cause of death worldwide and has a major impact on healthcare budgets. While early detection strategies may reduce the overall CVD burden through earlier treatment, it is unclear which strategies are (most) efficient.
aimThis systematic review reports on the cost effectiveness of recent early detection strategies for CVD in adult populations at risk.
methodsPubMed and Scopus were searched to identify scientific articles published between January 2016 and May 2022. The first reviewer screened all articles, a second reviewer independently assessed a random 10% sample of the articles for validation. Discrepancies were solved through discussion, involving a third reviewer if necessary. All costs were converted to 2021 euros. Reporting quality of all studies was assessed using the CHEERS 2022 checklist.
resultsIn total, 49 out of 5552 articles were included for data extraction and assessment of reporting quality, reporting on 48 unique early detection strategies. Early detection of atrial fibrillation in asymptomatic patients was most frequently studied (n = 15) followed by abdominal aortic aneurysm (n = 8), hypertension (n = 7) and predicted 10-year CVD risk (n = 5). Overall, 43 strategies (87.8%) were reported as cost effective and 11 (22.5%) CVD-related strategies reported cost reductions. Reporting quality ranged between 25 and 86%.
conclusionsCurrent evidence suggests that early CVD detection strategies are predominantly cost effective and may reduce CVD-related costs compared with no early detection. However, the lack of standardisation complicates the comparison of cost-effectiveness outcomes between studies. Real-world cost effectiveness of early CVD detection strategies will depend on the target country and local context. REGISTRATION OF SYSTEMATIC REVIEW: CRD42022321585 in International Prospective Registry of Ongoing Systematic Reviews (PROSPERO) submitted at 10 May 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.